A new generation
of cognitive medicine
Arcadia Medicine is engineering safe and effective mental health therapies
Arcadia was created to bring safe empathogens to patients and transform the mental health therapeutics space
Our mission is to scale safe and effective drug-assisted mental health therapies to reach patients in need across the globe
A better version of
MDMA
Our lead candidate is AM-1002
AM-1002 is in early development, the performance of AM-1002 has not be established nor has AM-1002 been approved by the FDA for any indication
Engineered to be safe with limited side effects
Developed to be non-neurotoxic, reduce hyperthermia, and have few cardiovascular side effects
Flexible dosing
Designed to accommodate a range of safe doses potentially allowing for more precise therapy and ongoing treatment options
Engineered for optimal effect
Designed to selectively release serotonin and oxytocin which is expected to drive therapeutic effect
Our Pipeline
Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed
Drug
Candidate properties
Status
AM-1002
(GAD)
Generalized Anxiety Disorder
Designed to be a non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile
Development
Phase I/II
Phase III
AM-1004
(MDD)
Major Depressive Disorder
Designed to be a short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile
Development
Phase I/II
Phase III
AM-1006
(SUD)
Substance Use Disorder
A subperceptual psychoactive drug designed to produce a short acting effect for use in a traditional hour-long therapeutic setting
Development
Phase I/II
Phase III
Our Pipeline
Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing psychedelic medicine
Drug
AM-1002 (GAD)
Generalized Anxiety Disorder
Indication
A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.
Status
Development
Preclinical
Phase I/II
Phase III
Drug
AM-1004 (MDD)
Major Depressive Disorder
Indication
A short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile
Status
Development
Preclinical
Phase I/II
Phase III
Drug
AM-1006 (SA)
Substance Abuse
Indication
A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.
Status
Development
Preclinical
Phase I/II
Phase III
Arcadia’s pharmacological model identifies optimal drug pharmacology profiles based on relevant receptor affinity, enantioselective metabolic profile, and existing safety and tolerance data.
Top candidates and combinations are evaluated based on their pharmacology, pharmacokinetics, and half-life to optimize expected safety and efficacy.
Our model generates extensive datasets, which are used to continuously curate and refine the prediction process, both before and during preclinical evaluation.
Next Gen
Discovery
Platform
Predict
Select
Learn
Investors
